PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays

PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays

Immune checkpoint blockade (ICB) drugs are a novel, effective treatment for advanced urothelial carcinoma. Worldwide, several different ICB drugs are approved, each developed and clinically validated with a specific PD-L1 compound diagnostic assay. As a result, PD-L1 testing workflows in routine pra...

Full description

Bibliographic Details
Main Authors: Harriet Evans, Brendan O’Sullivan, Frances Hughes, Kathryn Charles, Lee Robertson, Philippe Taniere, Salvador Diaz-Cano
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Pathology and Oncology Research
Subjects:
PD-L1
urothelial bladder carcinoma
predictive marker
Pembrolizumab
Atezolizumab
Online Access:https://www.por-journal.com/articles/10.3389/pore.2022.1610260/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2022.1610260/full

Similar Items